Over 100 distinct disease-associated mutations have been identified in the breast-ovarian cancer susceptibility gene BRCAI. Loss of the wild-type allele in >90% of tumors from patients with inherited BRCAI mutations indicates tumor suppressive function. The low incidence of somatic mutations suggests that BRCAI inactivation in sporadic tumors occurs by alternative mechanisms, such as interstitial chromosomal deletion or reduced transcription. To identify possible features of the BRCA1 genomic region that may contribute to chromosomal instability as well as potential transcriptional regulatory elements, a 117,143-bp DNA sequence encompassing BRCA1 was obtained by random sequencing of four cosmids identified from a human chromosome 17 specific library. The 24 exons of BRCAI span an 81-kb region that has an unusually high density of AJu repetitive DNA {41.5%), but relatively low density [4.8%) of other repetitive sequences. BRCAI intron lengths range in size from 403 bp to 9.2 kb and contain the intragenic microsatellite markers DI7S1323, DI7SI322, and DI7S855, which localize to introns 12, 19, and 20, respectively. In addition to BRCAI, the contig contains two complete genes: RhoT, a member of the rho family of GTP binding proteins, and VAT1, an abundant membrane protein of cholinergic synaptic vesicles. Partial sequences of the IAI-JB B-box protein pseudogene and lip JS, an interferon induced leucine zipper protein, reside within the contig. An L21 ribosomal protein pseudogene is embedded in BRCA1 intron 13. The order of genes on the chromosome is: centromere-lFP JS-VATI-P, hoT-BRCAI-IAI-JB-telomere.[The sequence data described in this paper have been submitted to GenBank under accession no. L78833.] Inherited mutations in the breast-ovarian cancer susceptibility gene, BRCA1 (Hall et al. 1990;Miki et al. 1994), confer a lifetime risk of breast cancer greater than 80% and an increased risk of ovarian cancer (Newman et al. 1988;Easton et al. 1993;Ford et al. 1994). Evidence for tumor suppressive function of BRCA1 derives from the high proportion (87%) of truncating germ-line mutations, which likely represent loss-of-function alterations (Castilla et